Formycon, a Germany-based biosimilar manufacturer, shared that its revenues for 2023 were 83% higher than in 2022, reaching a total of €77.7 million, according to its annual earnings report.
Dubinsky discusses findings from a post-hoc analysis of the head-to-head SEQUENCE trial of risankizumab versus ustekinumab in patients with Crohn disease refractory to anti-TNF therapy.
David Rubin, MD, leads the panel discussion on a head-to-head sequence study of rizankizumab vs ustekinumab in the treatment of CD, as well as approaches to choosing first-line treatment.
Our January 2024 Month in Review spotlights the FDA approval of a new indication of dupilumab (Dupixent) for pediatric eosinophilic esophagitis, new clinical trial data, and research about the prevention and management of IBD.
Results confirmed the long-term efficacy of ustekinumab maintenance in patients with ulcerative colitis, demonstrating consistent rates of symptomatic remission and endoscopic improvement with no new safety signals.